Dual Sphere Icon

Technical Capabilities

Deep specialisation across HEOR, RWE, and Global Market Access

Organised by what you need to solve - not by what services we offer.

01

Health Technology Assessment

The Context

Pharma and biotech teams preparing reimbursement submissions for national payer bodies. If you are preparing for a NICE Single Technology Appraisal, a G-BA dossier, a PBAC major submission, or a Singapore MOH application, this is the core service.

HTA Bodies

NICE (UK)G-BA (Germany)PBAC (Australia)CADTH (Canada)Singapore MOH / HBRAHITAP (Thailand)CDSCO / HTA India
Health Technology Assessment Diagram

What We Deliver

Submission-ready value dossiers, clinical and economic summaries, evidence gap analyses, and payer advisory support. We write for the specific body – not from a global template.

02

Pharmacoeconomic Modelling

The Context

Teams that need an economic model built from scratch, adapted from a global model, or validated for a specific market. Model development is not generic - the structure, time horizon, comparators, and inputs vary by HTA body.

Model Types

Markov cohort modelsPartitioned survival modelsDecision tree modelsDiscrete event simulationBudget impact modelsCost-of-illness analyses
Pharmacoeconomic Modelling Diagram

What We Deliver

Fully documented models in Excel with accompanying technical reports, validation summaries, and scenario analyses. Model structure decisions are documented and justified against the requirements of the specific payer.

03

Systematic Literature Review & Evidence Synthesis

The Context

Teams building the clinical evidence base for an HTA submission, an advisory board, or a publication. When there are no head-to-head trials - which is most of the time - evidence synthesis fills the gap.

Methodologies

PRISMA-compliant SLRsGRADE evidence assessmentPairwise meta-analysisFrequentist network meta-analysisBayesian NMA with non-informative and informative priorsIndirect treatment comparisonsMixed treatment comparisons
Systematic Literature Review & Evidence Synthesis Diagram

What We Deliver

Full SLR reports with PRISMA flow diagrams, evidence tables, risk of bias assessments, and NMA technical reports with heterogeneity and consistency analyses.

04

Real-World Evidence

The Context

Teams generating evidence of clinical effectiveness, safety, or healthcare resource utilisation from real-world data to support market access, post-launch commitments, or label expansion.

Study Designs

Retrospective cohort studiesDatabase analyses (administrative claims, electronic health records)Patient-reported outcome studiesBurden of illness studiesTreatment pattern analyses
Real-World Evidence Diagram

What We Deliver

Study protocols, statistical analysis plans, full study reports, and results narratives for payer or regulatory submission.

05

Medical Communications

The Context

Teams that need scientific content written for non-scientific audiences – payer slide decks, executive summaries, global value frameworks, or publication-ready abstracts.

Output Types

Global Value DossiersPayer evidence summariesHTA submission narrativesConference abstracts and postersJournal manuscriptsAdvisory board materialsInternal evidence communication tools
Medical Communications Diagram

What We Deliver

Publication-ready and payer-ready scientific documentation, from global value frameworks to peer-reviewed journal manuscripts and executive summaries.

06

Global Market Access Strategy

The Context

Teams entering new markets or preparing for multi-country launches who need a strategic plan - not just a submission document. This is upstream of the model and the dossier.

Strategic Focus

HTA readiness assessmentsEvidence gap analysesPricing and reimbursement strategyStakeholder mappingMarket entry sequencing
Global Market Access Strategy Diagram

What We Deliver

HTA readiness assessments, evidence gap analyses by market, pricing and reimbursement strategy frameworks, stakeholder mapping, and market entry sequencing recommendations across APAC, EU, and North America.

Working on a submission, a model, or a strategy?
Let's talk

We take on a focused number of engagements at any time to ensure senior-level attention on every project.

Start a conversation